Gilead Sciences said on Friday it was voluntarily withdrawing its drug, Trodelvy, for patients with a type of bladder cancer ...

The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for ...

Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...

Gilead is withdrawing the accelerated approval for its blockbuster antibody-drug conjugate Trodelvy for bladder cancer after ...

Gilead Sciences is set to withdraw Trodelvy's accelerated approval for metastatic urothelial cancer following unsatisfactory ...

Eli Lilly is making a series of investments in China to support its manufacturing and R&D operations. Gilead Sciences has ...

The antibody drug conjugate didn’t help patients live longer in a confirmatory trial, prompting a review of its conditional ...

Fintel reports that on October 17, 2024, Bernstein initiated coverage of Gilead Sciences (NasdaqGS:GILD) with a Outperform ...

As for Lilly ( LLY ), Bernstein said its outperform rating “hinges on what they can do with the cash they generate from ...

Gilead Sciences GILD has outperformed the market over the past 20 years by 3.74% on an annualized basis producing an average ...

Mount Gilead, NC, celebrates the 100th anniversary of its fire department, honoring seven firefighters for a combined 244 ...

Like its English-language predecessor, which launched in 2016, this Spanish-language patient community from MyHealthTeam is ...